Johnson & Johnson asked rival COVID-19 vaccine makers to probe clotting risks - WSJ

The U.S. federal health agencies had on Tuesday recommended pausing the use of Johnson & Johnson's vaccine for at least a few days after six women under the age of 50 developed rare blood clots after receiving the shot. Last week, European regulators said they were reviewing rare blood clots in four recipients of the J&J shot in the United States, after which, the WSJ report said, the company began to reach out to other vaccine makers.

Reuters | Washington DC | Updated: 16-04-2021 17:18 IST | Created: 16-04-2021 17:06 IST
Johnson & Johnson asked rival COVID-19 vaccine makers to probe clotting risks - WSJ
Representative image Image Credit: Twitter(@SAgovnews)

Johnson & Johnson had reached out to rival COVID-19 vaccine makers to join in an effort to study the risks of blood clots, the Wall Street Journal reported on Friday, citing people familiar with the matter.

AstraZeneca, which had been buffeted by similar blood-clotting concerns for weeks, agreed, while Pfizer Inc and Moderna executive declined, saying their vaccines appeared safe, the report said. (https://on.wsj.com/2Q7E4Ho) The U.S. federal health agencies had on Tuesday recommended pausing the use of Johnson & Johnson's vaccine for at least a few days after six women under the age of 50 developed rare blood clots after receiving the shot.

Last week, European regulators said they were reviewing rare blood clots in four recipients of the J&J shot in the United States, after which, the WSJ report said, the company began to reach out to other vaccine makers. Pfizer and Moderna also objected because they did not see the need to duplicate the efforts of agencies and companies that were already looking for blood-clot cases and investigating the cause, according to the report.

The specific adverse event has not been reported by those who received the Pfizer and Moderna vaccines, the companies had said. J&J, AstraZeneca, Pfizer, and Moderna were not immediately available for comments on the report.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


TRENDING

OPINION / BLOG / INTERVIEW

Blockchain in Healthcare: Opportunities and challenges

The use of blockchain in healthcare is a relatively new innovation with many of its uses still being explored and related technologies being developed, improved, and scaled. ...

Debate surrounding vaccine passports and development misses bigger picture

... ...

Blockchain vs IOTA: Looking for a better alternative

... ...

For stability, Iraq needs to crack down on corruption

... ...

Videos

Latest News

Georgia judge sets October trial in slaying of Ahmaud Arbery

A Georgia judge has scheduled an October trial for three white men charged with murder in the slaying of Ahmaud Arbery, a 25-year-old Black man who was chased and shot while running in the defendants neighbourhood last year.Superior Court J...

Frieze New York art fair: seeing Black lives differently

At the Frieze art fair in New York, over 60 leading galleries are paying tribute to social justice, showing works by the worlds most influential artists. The goal is to change how we see the world by examining arts role in portraying race a...

Brazil eyes new Pfizer deal next week for 100 million more COVID-19 shots

Brazil expects to sign a new deal next week with Pfizer Inc for 100 million more COVID-19 vaccine doses, a Health Ministry official said on Friday, which would double the U.S. drugmakers delivery to the Latin American country this year.Rodr...

NASA's new chief big on climate, hedges on 2024 moon landing

NASAs new administrator is big on tackling climate and diversifying the agencys workforce, but hedging on whether the US can put astronauts on the moon by 2024.In his first interview since becoming NASAs top official this week, former Sen. ...

Give Feedback